ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)

ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST) — VMCI valuation read

Composite valuation read on EXPRS2.ST: VMCI 42/100 against a Healthcare sector median of 50. The 8-point below-median print is the headline number for ExpreS2ion Biotech Holding AB (publ), and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for EXPRS2.ST: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on EXPRS2.ST: EXPRS2.ST trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -1.4x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

EXPRS2.ST fell 1.8% over the trailing 7 days, with a +0.8% read on a 30-day basis.